ReviewCells2018
Real-Time Imaging of Retinal Ganglion Cell Apoptosis.
Review in Cells, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07074782 (Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues: NEUROPA - a Retrospective Cohort Study
Who cites it
22 citing papers in PubMed, 44 citations in OpenAlex.
- The Machine Learning Classification of Retinal Ganglion Cell Dendritic Texture in a 3xTg-Alzheimer's Disease Mouse Model.Diagnostics (Basel, Switzerland) · 2026Article
- Identification of Chlamydia pneumoniae and NLRP3 inflammasome activation in Alzheimer's disease retina.Nature communications · 2026Article
- Article
- Emerging trends in long-acting sustained drug delivery for glaucoma management.Drug delivery and translational research · 2025Review
- Review
- Retinal Ganglion Cell Replacement in Glaucoma Therapy: A Narrative Review.Journal of clinical medicine · 2024Review
- Alzheimer's disease pathophysiology in the Retina.Progress in retinal and eye research · 2024Review
- Application of Proteomics Analysis and Animal Models in Optic Nerve Injury Diseases.Brain sciences · 2023Review
- Solving neurodegeneration: common mechanisms and strategies for new treatments.Molecular neurodegeneration · 2022Review
- Magnesium and Its Role in Primary Open Angle Glaucoma; A Novel Therapeutic?Frontiers in ophthalmology · 2022Review
- Retinal Dysfunction in Alzheimer's Disease and Implications for Biomarkers.Biomolecules · 2021Review
- Review
- Discovery and clinical translation of novel glaucoma biomarkers.Progress in retinal and eye research · 2021Review
- Hemispherical Microelectrode Array for Ex Vivo Retinal Neural Recording.Micromachines · 2020Article
- Article
- Innovative IOP-Independent Neuroprotection and Neuroregeneration Strategies in the Pipeline for Glaucoma.Journal of ophthalmology · 2020Review
- Protect, Repair, and Regenerate: Towards Restoring Vision in Glaucoma.Current ophthalmology reports · 2020Review
- A recommended "minimum data set" framework for SD-OCT retinal image acquisition and analysis from the Atlas of Retinal Imaging in Alzheimer's Study (ARIAS).Alzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
- [Unmet research and developmental needs in ophthalmology : A consensus-based road map of the European Vision Institute for 2019-2025].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2019Review
- The Retina as a Window or Mirror of the Brain Changes Detected in Alzheimer's Disease: Critical Aspects to Unravel.Molecular neurobiology · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monitoring real-time apoptosis in-vivo is an unmet need of neurodegeneration science, both in clinical and research settings. For patients, earlier diagnosis before the onset of symptoms provides a window of time in which to instigate treatment. For researchers, being able to objectively monitor the rates of underlying degenerative processes at a cellular level provides a biomarker with which to test novel therapeutics. The DARC (Detection of Apoptosing Retinal Cells) project has developed a minimally invasive method using fluorescent annexin A5 to detect rates of apoptosis in retinal ganglion cells, the key pathological process in glaucoma. Numerous animal studies have used DARC to show efficacy of novel, pressure-independent treatment strategies in models of glaucoma and other conditions where retinal apoptosis is reported, including Alzheimer’s disease. This may forge exciting new links in the clinical science of treating both cognitive and visual decline. Human trials are now underway, successfully demonstrating the safety and efficacy of the technique to differentiate patients with progressive neurodegeneration from healthy individuals. We review the current perspectives on retinal ganglion cell apoptosis, the way in which this can be imaged, and the exciting advantages that these future methods hold in store.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.